# GenSight Biologics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gensight-biologics-s-a

- Industry: Pharmaceuticals
- Headquarters: Paris, France
- Website: www.gensight-biologics.com
- Total disclosed funding: $62M
- Latest round: Series B (Oct 29, 2015)
- Investors on record: 10

## About

Based in France, GenSight Biologics S.A. is a biotechnology company focused on innovative gene therapy solutions to treat neurodegenerative ophthalmic diseases, enhancing the quality of life for individuals affected by visual impairment.GenSight Biologics specializes in gene therapy for ophthalmic conditions, founded in 2012 in Paris, France. In December2025, GenSight Biologics S.A. raised EUR 2.89 million in venture funding from Heights Capital Management, Invus, and Alumni Capital Network. Their primary product offerings include GS010, a gene therapy based on lenadogene nolparvovec specifically designed for Leber Hereditary Optic Neuropathy (LHON), and GS030, which utilizes optogenetics technology to restore vision in patients with retinal degenerative diseases. These therapies are intended to provide innovative treatment options for individuals suffering from vision loss caused by genetic conditions. The company targets markets across Europe and North America, collaborating with healthcare professionals and institutions to ensure accessibility of their therapies.GenSight Biologics generates revenue through the commercialization of its gene therapy products, particularly GS010 and GS030. The company's revenue model focuses on partnerships with healthcare providers and research institutions to facilitate delivery of its therapies, reflecting the innovative nature of their products.GenSight Biologics plans to leverage recent funding to support the development and commercialization of new products aimed at expanding their therapeutic offerings. The company is focused on launching new gene therapies and expanding into new markets, particularly in Europe and North America, to address unmet medical needs.

## Funding rounds

- Series B, Oct 29, 2015, $35M — Abingworth, Versant Ventures, Novartis Venture Fund, Fidelity Investments, Sphera Fund Management, Jennison Associates, HealthCap, Bpifrance Investissement, Perceptive Advisors, Vitavest S.à.r.l.
- Series A, Jan 28, 2014, $2.3M — Bpifrance Investissement
- Series A, Mar 21, 2013, $24M — Abingworth, Versant Ventures, Novartis Venture Fund, Vitavest S.à.r.l.

## Investors

- Abingworth (https://capitalatlas.ai/funds/abingworth) — Series A, Series B
- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A, Series B
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series A, Series B
- Vitavest S.à.r.l. — Series A, Series B
- Bpifrance Investissement (https://capitalatlas.ai/funds/bpifrance-investissement) — Series A, Series B
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series B
- Sphera Fund Management — Series B
- Jennison Associates — Series B
- HealthCap — Series B
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series B